FDA on Phase IV trials
This article was originally published in The Tan Sheet
The design and implementation of post-marketing commitments will be studied by an outside contractor as part of a new FDA initiative to evaluate and improve the Phase IV commitment process, according to Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD. The intiative will "evaluate and perhaps improve how we use post-marketing commitments," Gottlieb said during an American Enterprise Institute discussion Feb. 8 in Washington, D.C. The agency currently is in negotiations and expects to announce the contract for the one-year study in the next few weeks. "The objectives of this effort are to evaluate the consistencies of the processes within the divisions, across divisions within FDA and also across different medical centers for requiring, requesting and facilitating as well as reviewing post-market commitments," Gottlieb said...
You may also be interested in...
A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.
Despite a slight increase in revenue, South Africa’s Adcock continues to struggle as it reports a continued drop in gross profit. The company expects the economy to remained constrained due to COVID-19, but is eagerly anticipating recovery with the government’s vaccine roll-out.
Round-up of the latest news across EMEA, including two deals for Bayer in Egypt and Saudi Arabia; Orkla's acquisition of NutraQ; and Uriach's deal for Sidroga.